
argenx SE Net Income | ARGX
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income argenx SE
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.29 B | 833 M | -295 M | -710 M | -408 M | -529 M | -163 M | -66.6 M | -28.1 M | -21.4 M | -15.3 M | -10.3 M | -6.13 M | -9.7 M | -3.46 M |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.29 B | -710 M | -9.38 M |
Quarterly Net Income argenx SE
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.29 B | 415 M | 833 M | -32.5 M | -295 M | -123 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.29 B | -295 M | 348 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Jaguar Health
JAGX
|
-54 K | $ 0.35 | -8.69 % | $ 816 K | ||
|
Arvinas
ARVN
|
-81 M | $ 6.77 | -0.73 % | $ 480 M | ||
|
Cerus Corporation
CERS
|
-15.6 M | $ 1.95 | 2.63 % | $ 372 M | ||
|
Beam Therapeutics
BEAM
|
-80 M | $ 21.03 | 1.82 % | $ 2.08 B | ||
|
Inhibrx
INBX
|
-241 M | $ 68.87 | -7.16 % | $ 3.25 B | ||
|
Royalty Pharma plc
RPRX
|
771 M | $ 68.76 | 0.12 % | $ 29.6 B | ||
|
Entera Bio Ltd.
ENTX
|
-11.4 M | $ 3.24 | 8.0 % | $ 150 M | ||
|
Revolution Medicines
RVMD
|
-1.13 B | $ 159.7 | -1.84 % | $ 30.4 B | ||
|
Flexion Therapeutics, Inc.
FLXN
|
-114 M | - | - | $ 459 M | ||
|
Legend Biotech Corporation
LEGN
|
-297 M | $ 16.25 | 0.87 % | $ 5.99 B | ||
|
CytomX Therapeutics
CTMX
|
-17.4 M | $ 1.91 | -1.55 % | $ 263 M | ||
|
Krystal Biotech
KRYS
|
205 M | $ 314.77 | 5.43 % | $ 9.11 B | ||
|
Kura Oncology
KURA
|
-279 M | $ 7.34 | -2.07 % | $ 644 M | ||
|
Inhibikase Therapeutics
IKT
|
-48.3 M | $ 1.39 | 0.36 % | $ 137 M | ||
|
Phathom Pharmaceuticals
PHAT
|
-221 K | $ 5.31 | -3.45 % | $ 387 M | ||
|
Heron Therapeutics
HRTX
|
-20 M | $ 0.27 | -3.26 % | $ 45 M | ||
|
Inovio Pharmaceuticals
INO
|
-85 M | $ 1.69 | 3.37 % | $ 79.2 M | ||
|
Corvus Pharmaceuticals
CRVS
|
-15.3 M | $ 10.19 | 0.22 % | $ 805 M | ||
|
SIGA Technologies
SIGA
|
23.3 M | $ 2.81 | 2.75 % | $ 201 M | ||
|
Aytu BioScience
AYTU
|
-14.3 M | $ 2.66 | -0.19 % | $ 32.8 M | ||
|
Heat Biologics, Inc.
HTBX
|
-26 M | - | -5.76 % | $ 99.8 M | ||
|
Innoviva
INVA
|
271 M | $ 18.36 | 0.3 % | $ 1.24 B | ||
|
BioCardia
BCDA
|
-8.23 M | $ 0.77 | -2.06 % | $ 5.13 M | ||
|
Kindred Biosciences, Inc.
KIN
|
-21.8 M | - | 0.11 % | $ 419 M | ||
|
Syndax Pharmaceuticals
SNDX
|
-285 M | $ 8.55 | -7.07 % | $ 741 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-12.1 M | $ 1.72 | -7.77 % | $ 11 B | ||
|
Shineco, Inc.
TYHT
|
-6.63 M | - | -3.90 % | $ 97.2 M | ||
|
ORIC Pharmaceuticals
ORIC
|
-129 M | $ 7.66 | -4.25 % | $ 673 M | ||
|
Oramed Pharmaceuticals
ORMP
|
75.3 K | $ 3.9 | 0.78 % | $ 161 M | ||
|
Certara
CERT
|
-1.6 M | $ 11.25 | 1.72 % | $ 1.8 B | ||
|
PainReform Ltd.
PRFX
|
-5.02 M | $ 0.63 | -4.8 % | $ 408 K | ||
|
Intec Pharma Ltd
NTEC
|
-14.1 M | - | -12.45 % | $ 17.7 M | ||
|
Anika Therapeutics
ANIK
|
-11 M | $ 13.74 | 6.89 % | $ 197 M | ||
|
Prothena Corporation plc
PRTA
|
-244 M | $ 8.38 | 1.39 % | $ 451 M | ||
|
Aprea Therapeutics
APRE
|
-12.6 M | $ 0.46 | 2.6 % | $ 3.01 M | ||
|
Galectin Therapeutics
GALT
|
-30.8 M | $ 3.0 | 2.92 % | $ 192 M | ||
|
Processa Pharmaceuticals
PCSA
|
-13.6 M | $ 1.7 | -2.3 % | $ 2.23 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
99.7 M | $ 67.94 | -3.04 % | $ 7.06 B | ||
|
Progenity, Inc.
PROG
|
-193 M | - | -3.47 % | $ 164 M | ||
|
China SXT Pharmaceuticals
SXTC
|
-6.21 M | $ 2.84 | -0.7 % | $ 1.93 M | ||
|
Genprex
GNPX
|
-16.2 M | $ 1.73 | 3.56 % | $ 1.61 M | ||
|
Strongbridge Biopharma plc
SBBP
|
-45.1 M | - | 1.52 % | $ 136 M | ||
|
Takeda Pharmaceutical Company Limited
TAK
|
108 B | $ 21.27 | -1.71 % | $ 33.6 B | ||
|
Protara Therapeutics
TARA
|
-57.4 M | $ 2.33 | 0.22 % | $ 99.8 M | ||
|
Innate Pharma S.A.
IPHA
|
-49.2 M | $ 1.0 | -24.81 % | $ 89.6 M | ||
|
Seneca Biopharma, Inc.
SNCA
|
-16.3 M | - | -1.19 % | $ 28.7 M | ||
|
BioMarin Pharmaceutical
BMRN
|
349 M | $ 61.57 | 5.22 % | $ 11.8 B | ||
|
Bio-Techne Corporation
TECH
|
182 M | $ 72.74 | 0.15 % | $ 11.3 B | ||
|
Matinas BioPharma Holdings
MTNB
|
-10.3 M | $ 0.91 | 6.35 % | $ 4.98 M |